iPSC Genome Editing by CRISPR-SNIPER
CRISPR-Cas9 is the ideal gene-editing system for the establishment of disease-relevant models, as it allows the modification of cells in their pluripotent state. However, the single base-pair mutations induced by this system are too small to support the use of screening genes. This means that many clones must be sequenced in order to identify those that contain your desired mutation; increasing the time spent optimizing cell culture conditions.
The development of SNIPER† has overcome this obstacle by increasing the number of positive clones detected during the initial screening process. In fact, SNIPER is so accurate it can increase the fraction of positive clones detected 300-fold, reducing the number of cells for sequencing. In collaboration with GenAhead Bio®, REPROCELL can now offer CRISPR-SNIPER as part of our stem cell services.
† Specification of Newly Integrated Position and Exclusion of Random-Integration.
Benefits of CRISPR-SNIPER
The addition of SNIPER to you CRISPR gene-editing allows:
✓ Introduction of mutations into iPSCs and cell-lines
✓ Increased probability that clones possess your desired mutation
✓ Insertion of homogeneous and heterogenous mutations
✓ Multiplex gene knock-out, reducing cell-line passagenumber
✓ Accelerated optimization of culture conditions saving you time and resources
With our SNIPER projects, REPROCELL will also provide an isogeneic control line to aid the complete characterization of your mutation. A
Advancing Human Health Together
At REPROCELL we are committed to the advancement of human health through biomedical innovation and discovery. You can learn more about the science behind SNIPER in our interview with its creator, Dr Tsukasa Sugo, or in our BioInformant article by Cade Hildreth: “Development of iPSC-derived disease models”.
- Jiang et al. RNA-Guided Editing of Bacterial Genomes Using CRISPR-Cas Systems. Nature Biotechnology 31:3 (2013).
Note: The modified cells are developed, manufactured or supplied by GenAhead Bio Inc. under license from ERS Genomics Limited.